



**AMENDMENTS TO THE CLAIMS:**

*This listing of the claims below will replace all prior versions and listing of claims in this application.*

1. **(Currently Amended)** Pyridinylpyrazolopyrimidinone derivative represented by the following formula (IA) or (IB):



(IA)



(IB)

wherein:

R<sup>1</sup> is ~~a~~ substituted or unsubstituted ~~unsubstituted~~ C<sub>3</sub>-C<sub>8</sub> cycloalkyl group or tert-butyl group;

R<sup>2</sup> is a hydrogen atom or C<sub>1</sub>-C<sub>3</sub> alkyl group;

R<sup>3</sup> is a group: -NR<sup>5</sup>R<sup>6</sup>, -C(=O)R<sup>7</sup> or -S(O)<sub>0-2</sub>R<sup>8</sup>;

R<sup>4</sup> is a hydrogen atom or C<sub>1</sub>-C<sub>3</sub> alkoxy group which is unsubstituted or substituted by one or more fluorine atom(s);

R<sup>5</sup> and R<sup>6</sup> are, same or different from each other, a hydrogen atom, substituted or unsubstituted ~~unsubstituted~~ C<sub>1</sub>-C<sub>6</sub> alkyl group, substituted or unsubstituted ~~unsubstituted~~ acyl group, substituted or unsubstituted ~~unsubstituted~~ heterocycloalkyl group, and substituted or unsubstituted ~~unsubstituted~~ heterocycloalkyl ring is formed with a nitrogen atom which is binding R<sup>5</sup> and R<sup>6</sup>;

R<sup>7</sup> is a group: -OR<sup>9</sup> or -NR<sup>5</sup>R<sup>6</sup>;

R<sup>8</sup> is a hydrogen atom, a halogen atom, a group: -NR<sup>5</sup>R<sup>6</sup>, substituted or unsubstituted ~~unsubstituted~~ C<sub>1</sub>-C<sub>6</sub> alkyl group, or substituted or unsubstituted ~~unsubstituted~~ aryl group;

R<sup>9</sup> is a hydrogen atom or substituted or unsubstituted ~~unsubstituted~~ C<sub>1</sub>-C<sub>6</sub> alkyl group; or pharmaceutically acceptable salts or solvates thereof.

2. (Original) The compound represented by the formula (IA) according to claim 1.

3. (Original) The compound represented by the formula (IB) according to claim 1.

4. (Currently amended) The compound according to claim 1, ~~2 or 3~~, in which R<sup>1</sup> is a cyclohexyl group or cycloheptyl group.
5. (Currently amended) The compound according to claim 1 ~~to any one of claims 1 to 4~~, in which R<sup>2</sup> is a methyl group.
6. (Currently amended) The compound according to claim 1 ~~any one of claims 1 to 5~~, in which R<sup>4</sup> is a methoxy or ethoxy group.
7. (Currently amended) The compound according to claim 1 ~~any one of claims 1 to 6~~, in which R<sup>3</sup> is a group -NR<sup>5</sup>R<sup>6</sup>.
8. (Currently amended) A pharmaceutical composition comprising ~~containing~~ a compound according to claim 1 ~~any one of claims 1 to 7~~, or pharmaceutically acceptable salts or solvates thereof as active ingredient.
9. (Currently amended) A PDE 7 inhibitor comprising ~~containing~~ a compound according to claim 1 ~~any one of claims 1 to 7~~, or pharmaceutically acceptable salts or solvates thereof as active ingredient.